Harpoon Therapeutics Inc. has expanded an immuno-oncology drug discovery collaboration with AbbVie to include an option license for a B-cell maturation antigen (BCMA)-targeting T-cell engager poised to enter the clinic in 2020 for multiple myeloma.
The option deal is part of an expanded collaboration between the two partners that was announced on 21 November. AbbVie...








